|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 12, Num. 2, 2007, pp. 115-122
|
Middle East Fertility Society Journal, Vol. 12, No. 2, 2007, pp. 115-122
Clomiphene
citrate response in PCOS patients with
abnormal lipid profile and impaired glucose
tolerance test
Maida Y. Shamdeen, M.R.C.O.G., F.R.C.O.G., Luma A. Mohammad, F.I.B.O.G.
Mosul medical college,
and Albatool Maternity Teaching Hospital, Mosul, Iraq
Correspondence: Maida Shamdeen, MRCOG/FRCOG, Obstetric & Gynecology Department, Dohuk Medical College, Dohuk, Iraq.
Received on February 13, 2006; revised and accepted on March 12, 2007
Code Number: mf07020
ABSTRACT
Objective: To assess the clomiphene citrate(CC)
response to 200mg in women not responding to 150mg for ovulation induction in
PCOS women with abnormal lipid profile and impaired glucose tolerance test, and
to assess the postprandial triglyceride response to high fat meal in PCOS women
Design: controlled clinical study.
Setting: infertile PCOS women attending
infertility centre in Al-Batool maternity Teaching Hospital.
Materials
and methods: 50
infertile women with PCOS, who failed to respond to 150 mg clomiphene citrate
(CC) fore 4cycles (25 non-obese and 25 over weight) were given 200mg of CC, and
25 healthy women as controls, were selected. Assessment for; Clinical,
anthropometric measurement, fasting serum glucose, fasting lipid profile, oral
glucose tolerance test, postprandial triglyceride, cholesterol, high and low
density lipoprotein, hormonal assay, and ovarian ultrasound.
Results: Both obese and non-obese PCOS women with
CC resistant (CCr) to 150mg when 200mg is used had a significant higher
waist-to-hip ratio than controls at P≤0.05. PCOS women had higher levels of
fasting, and 2-hour postprandial blood sugar (2h PPBS) and high-density
lipoproteins (HDL) levels in a significant difference at P≤0.05. High-density lipoprotein was significantly lower in
PCOS women than controls at P≤0.05. Clomiphene citrate response (CCR)
was significantly less in PCOS groups with impaired glucose tolerance (IGT)
33.4% than those with normal blood sugar (BS) (81.8%), and higher in women with
type 2 diabetes mellitus (DM) as (100%) were (CCr). CCr was more in PCOS women
with abnormal lipid profile compared to normal (71.4% in abnormal triglyceride
(Tg), 78.2% in abnormal cholesterol (Ch) and 67.7% with abnormal HDL.
Conclusion: PCOS women with IGT test; non-insulin
dependent DM and abnormal lipid profile had more CCr in ovulation induction,
than those with normal blood sugar and lipid profile. PCOS women had
postprandial hypertriglyceridemia that is related to high waist-to-hip ratio,
and insulin resistance regardless of obesity.
Key
words: PCOS, clomiphene
citrate, abnormal lipid profile, impaired glucose tolerance.
Polycystic
ovary syndrome (PCOS) is most frequent encountered endocrinopathy in women at
reproductive age (1). The following characteristics are very often associated
with PCOS; hirsutism, polycystic ovaries, obesity and infertility (2).
PCOS is associated with
a significant morbidity of both reproductive and non reproductive events, and
increases morbidity, and mortality by the time of menopauses. PCOS women have
profound insulin resistance, prevalence of IGT in 31-35%, type 2 diabetes
mellitus(DM) in 75-100%, Lipid
abnormalities, cardiovascular disease, and endometrial carcinoma (2, 3). PCOS
women do not ovulate in predictable manner, and produce excessive quantities of
testosterone (4). It has been found that 38-50% of PCOS women are overweight,
with body mass index (BMI)>25 kg/m2 which increase directly with
the serum luteinizing hormone (LH) concentration greater than 10IU/L(5,6,7). It
was found that PCOS is a metabolic as well as reproductive disorder (8). The
association between disorders of carbohydrate metabolism and hyperandrogenism
was first described in 1921 by Achard and Thiers, and was reported to occur
frequently in women with hyperandrogenism and DM by Kierland et al in 1947.
Brown and Winkelmann noted in 1968 that it was insulin-resistance DM, which got
genetic basis (9, 10), and in 1980 Burghen and colleagues reported that there
are significance positive linear correlations between insulin and androgen
levels (11). Hyper insulinemia; which directly reduce serum levels of sex
hormone binding globulin (SHBG), has been shown in several epidemiological studies
that there is increase risk factors for cardiovascular disease such as; central
obesity, hypertension hyperglyceridemia, low level of (HDL) cholesterol,
abnormal glucose metabolism, and hyperinsulinemia (12). Most PCOS women ovulate
intermittently and are deficient in progesterone secretion may take longer to
conceive, with an increase miscarriage rate, the mechanism of which is poorly
understood (13).
Several
biochemical abnormalities were noticed all of which contribute to increased
ovarian production of androgens; as testosterone, 17 hydroxy progesterone
(17O.H.P), Dehydroepiandrosterone (DHEA) and Dehydroepiandrosterone sulphate
(DHEAS), growth hormone (GH), insulin growth factor 1 (IGF1)(14). Insulin is
progonadotropins; in synergy with LH they act on ovarian theca stroma cells to
stimulate the expression of cytochromes P450c17 and excessive androgen
production (15). Insulin resistance in PCOS is not due to obesity primarily or
hyperandrogenism (16). The cellular mechanism of insulin resistance in PCOS
suggested being due to reduced binding of insulin to its receptor, and/or
reduced insulin mediated glucose transport, suggesting a post receptor defect
(17). In PCOS reduced amount of follicular fluid (IGF BP-1) potentiates IGF
mediated ovarian androgen secretion (18). The presence of obesity and insulin
resistance may predispose women to coronary heart disorder) (19).
The
majority of women with PCOS have anovulatory infertility; this may be treated
effectively but is not a simple manner (20). However up to 10% of women may
have CCr and fail to response to doses as high as 150 mg daily for 5 days, due
to lack of adequate ovarian response 16. Recently promising results have been
demonstrated with the use of metformin and insulin sensitizing agents such as
troglitazone and D chiro-inositol (16, 20).
Aims
of the work: To assess CCR to 200mg CC in PCOS women failed to respond to
150mgCC for ovulation induction, with impaired glucose tolerance test and
abnormal lipid profile, and to assess the role of postprandial lipemia and
important of waist-to-hip ratio in PCOS women.
MATERIALS AND METHODS
From
first of January 2003 to the first of January 2004, fifty infertile PCOS women,
aged 18-37 years, were selected randomly according to the day of presentation
in the infertility clinic in Al-Batool teaching Hospital. All women were in
good health for at least one month before study, not tacking any medication
known to affect sex hormone or carbohydrate and lipid metabolism. The criteria
of PCOS were based on the finding of polycystic ovaries appearance on
ultrasound, in oligomenorrhea, hirsutism, and serum testosterone > 0.7
ng/ml. The study groups; Twenty-five PCOS women had normal weight and BMI
between18-25 kg/m2, and Twenty-five were over weight BMI between 25 -30 kg/m2.
The
control group consists of 25 healthy women, had regular menstrual cycle, not
hirsute, and had normal weight and BMI between18-25 kg/m2. To
control for conditions altering insulin action and lipid profile, controlled
women did not engage in regular aerobic exercise, nor did have history of
hypertension, DM, cardiovascular disease, and first-degree relative with these
disease.
Table 1. Descriptive characteristics
of PCOS groups and control.
Variable |
PCOS
Over
weight
|
PCOS
Normal
|
Control |
|
|
|
|
|
|
|
|
Age (year) |
24.1 ± 0.51 |
23.59
± 0.54 |
23.62
±0.78 |
|
|
|
|
BMI (Kg/m2) |
27.28
± 0.36c |
23.37
± 0.57b |
20.54
± 0.21a |
|
|
|
|
Testosterone |
2.67
± 0.15 c |
1.82 ±
0.13b |
0.53 ±
0.02a |
|
|
|
|
LH/FSH |
2.15 ±
0.02 c |
1.77 ±
0.03b |
0.83 ±
0.02a |
|
|
|
|
W/H |
0.90 ±
0.03 b |
0.83 ±
0.01b |
0.66 ±
0.01a |
|
|
|
|
FBS |
7.11 ±
0.14 c |
4.83 ±
0.17b |
3.72 ±
0.06a |
|
|
|
|
2h.BG |
9.16 ±
0.29 c |
6.99 ±
0.21b |
5.59 ±
0.10a |
|
|
|
|
Tg |
2.43 ±
0.09 c |
1.78 ±
0.09b |
1.35 ±
0.05a |
|
|
|
|
Ch |
5.19 ±
0.25 c |
4.03 ±
0.18b |
3.33 ±0.06a |
|
|
|
|
HDL |
0.75 ±
0.02 b |
1.08 ±
0.12b |
1.94 ±
0.15a |
|
|
|
|
LDL |
3.75 ±
0.21 b |
3.15 ±
0.22b |
1.56 ±
0.33a |
|
|
|
|
Atherogenic index |
7.14 ±
0.46 b |
5.74 ±
0.59b |
3.82±
0.62a |
|
|
|
|
VLDL |
0.45 ±
0.02 c |
0.35 ±
0.02b |
0.27 ±
0.01a |
Values are mean±SE.
Different letters horizontally means significant difference between the groups
and at P ≤ 0.05.
Anthropometric Measurements; Weight and height were
recorded when the women were wearing light
clothing and without shoes. Accurate balance scales were used and weight was
recorded to the nearest 0.1 kg. Height was recorded to the nearest centimeters
using measuring rod in the same room, also waist and hip were recorded. Subject
was breathed quietly and normally; dresser marker measuring tapes was used
tacking care that it was applied horizontally. Waist girth was measured at the
mid point between iliac crest and the lower margin of 10th ribs. An approximate
indicator of this level was ascertained by asking the subject to bend sideways.
Hip girth was recorded as the maximum circumference around the buttock
posteriorly and indicated anteriorly by symphysis pubis.
Modified Oral Glucose Tolerance Test (OGTT) was done; by a
standard 75g oral glucose given to the subject after 10-12 hr overnight fasting
at day 2 or 3 of menstrual cycle. Venous blood sample was taken before and 2 hr
after glucose load for fasting (FBS) and postprandial blood sugar (PPBS)
measurements.
High Fat Meal Test; The high fat meal was carried out 3
days after the OGTT, after 10-12 hr overnight fast, in the morning (about 8:30
am) the subject were given a high fat meal consisting of 66% as fat, 18% as
carbohydrate, and 16% as protein. It consisted of wheat bread with margarine
and pasteurized cream, whole milk and cooked egg. Blood samples for
triglycerides, cholesterol and HDL were drawn before the meal and at (4, 5 and
6 hrs) after meal without allowing further eating.
Biochemical Assessment; venous blood 5ml taken each time,
the sera separated for determination of fasting lipid profiles (total
cholesterol, total triglyceride (Tg), LDL cholesterol, very low density
lipoprotein-cholesterol VLDL, HDL cholesterol) and atherogenic index was
determined. Serum was stored at 20oC for hormone analysis (LH, FSH,
and Testosterone). They were determined by combines an enzyme immunoassay
sandwich method with a final florescent detection (ELFA). Results are
automatically calculated by VIDAS in relation to the calibration curve stored
in memory and then printed out.
Lipid Profile; Serum Tg and Cholesterol (Ch) were
determined by commercial enzymatic methods, kit used was Biomerieux Ltd.,
France. HDL was measured after precipitation of chylomicrons and lipoproteins
of very low-density lipoprotein (VLDL), and LDL with phosphotungstic acid and
magnesium ions (Biomerieux, France). Values determined as follow; VLDL =Tg/5,
LDL = Total cholesterol - (HDL + VLDL), and Atherogenic index = Cholesterol /
HDL.
Table2. 6hr postprandial
triglyceride for PCOS groups and control.
Groups |
Tg (6hr. mmol/L) |
|
|
Overweight PCOS |
16.75 ± 1.46ab |
Normal weight PCOS |
13.61 ± 3.02ab |
Control |
9.95 ± 1.71 |
Different superscripts (a
and b) represent statistically significant differences between the groups at
p<0.0001. a. Overweight or normal weight vs. controls, b. Overweight vs.
normal weight.
Table 3. Response to ovulation
induction by 200mg CC in PCOS groups.
Parameters |
No response |
Positive response |
P-value |
Significance |
|
|
|
|
|
BMI |
26.79 ± 0.51 |
24.31 ± 0.59 |
< 0.01 |
S |
Testosterone |
2.40 ± 0.20 |
2.13 ± 0.14 |
> 0.05 |
NS |
LH/FSH |
2.03 ± 0.05 |
1.91 ± 0.04 |
> 0.05 |
NS |
W/H |
0.86 ± 0.03 |
0.86 ± 0.02 |
> 0.05 |
NS |
FBS |
6.53 ± 0.25 |
5.58 ± 0.28 |
< 0.05 |
S |
GTT |
8.73 ± 0.32 |
7.63 ± 0.32 |
< 0.05 |
S |
Tg |
2.41 ± 0.08 |
1.89 ± 0.11 |
0.001 |
S |
CH |
5.19 ± 0.24 |
4.20 ± 0.21 |
< 0.01 |
S |
HDL |
0.69 ± 0.01 |
1.07 ± 0.10 |
< 0.01 |
S |
LDL |
3.79 ± 0.22 |
3.22 ± 0.21 |
> 0.05 |
NS |
ATH |
7.56 ± 0.33 |
4.82 ± 0.57 |
0.001 |
S |
VLDL |
0.45 ± 0.02 |
0.36 ± 0.02 |
< 0.01 |
S |
Note: Values are mean ±
stander error mean (SEM) significant difference between groups at P ≤ 0.05
Lipid Profile Normal Range for
our lab was; Serum cholesterol (3.9-6.5) mmol/L, Tg (0.9-2.4) mmol/L, HDL
(0.9-1.4) mmol/L, LDL (1.8-4.3) mmol/L, VLDL (<0.93) mmol/L, and Atherogenic
index (<5).
Glucose tolerance (GT) was assessed by WHO criteria. The
subjects were classified into the following three groups: Non diabetic group
with FBS <6.1 mmol/L or 2 hour blood sugar (2hr BS) <7.8 mmol/L, Diabetic
group with FBS≥7.8 mmol/L or 2hr BS≥11.1
mmol/L following OGTT, and impaired Glucose Tolerance (IGT) group included
subjects who had 2hr BS values ranges from 7.8-11.06 mmol/L following OGTT.
Induction
of Ovulation; CC was used in induction of ovulation, it was orally administered
by the women in a maximum dose of 200 mg in 2 divided dose for 5 days from day
2 of the menstrual cycle for 4 months (patients previously failed to ovulate in
smaller dose). During each cycle, determination of mature follicle was
attempted by serial ultrasounds every other day. Evidence of follicular growth
of at least a single dominant follicle obtained by ultrasound at mid cycle 5-10
day after the last dose of CC (mature follicle considered when 17-22 mm was the
diameter).
RESULTS
The
clinical and biochemical characteristics of normal weight, overweight PCOS
groups and control group were summarized in table1. Results of the three groups
were also compared using Duncan multiple range test at p≤0.05.The results showed
that there was no significant difference in mean age; between PCOS group and
control group, while PCOS group had significantly higher waist-to-hip ratio
than control group (over weight vs. control) and (non obese vs. control). FBS and
2hr PPBS level were significantly higher in PCOS normal weight women than
control and much higher in PCOS overweight women.
Table 4. Response to 200mg CC in
both normal and overweight PCOS groups
CC response |
Total |
Normal weight
No. (%)
|
Overweight
No. (%)
|
|
|
|
|
Positive(CCR) |
26 |
19 (73) |
7 (27) |
Resistant(CCr) |
24 |
6 (27) |
18 (73) |
Total |
50 |
25 (100) |
25 (100) |
Table 5. CCR to 200mg CC in women
with IGT test and NIDM
CC Response |
Normal PG 2h
No.(%)
|
I GTT 2h
No.(%)
|
Diabetic
No.(%)
|
P-value |
|
|
|
|
|
Positive(CCR) |
18 (81.8)
|
8 (33.4)
|
0 (0)
|
P < 0.05 |
Resistant(CCr) |
4 (18.2) |
14 (66.6)
|
6 (100)
|
|
Total |
22 (100)
|
22 (100)
|
6 (100)
|
|
The
lipid profile, fasting Tg and Fasting total cholesterol levels were
significantly higher in PCOS groups and the highest value was observed in
overweight subjects (overweight vs. non-obese) and (overweight vs. control).
Fasting HDL levels were significantly lower in PCOS groups but no significant
differences within PCOS groups were observed. VLDL and LDL levels were significantly
higher in PCOS groups and significant differences were observed between control
and PCOS groups. Atherogenic index was significantly higher in PCOS groups
between the control and PCOS groups.
The
result of Pearson correlation analysis in overall PCOS groups shows: A
significant correlation;(p<0.0001) between BMI and Tg, (p<0.01) between
W/H and Tg , (p<0.01) between testosterone and Tg , (p<0.0001) between
FBS and Tg ,and (p<0001) between 2h PG and Tg . Postprandial Triglyceride
Response in the 2 PCOS groups and control were summarized in Table 2. Results
showed significant difference between overweight PCOS groups and normal weight
PCOS group with control (p<0.0001). On the other hand, a significant
difference between the two PCOS groups was found at (p<0.0001).
The
responses to induction of ovulation by 200mg CC (CCR) in PCOS women are
summarized in Table 3. There was a significant difference to CCR in relation to
BMI at p<0.01, A significant differences to CCR was noticed in relation to;
FBS, and 2hrBS at P<0.05. Also CCR showed significant differences in
relation to the lipid profile (Tg, cholesterol, HDL, and VLDL) at P<0.001,
and the atherogenic index at P<0.001. On the other hand there was no
significant difference between CCR with LDL.
CCR
in relation to weight is shown in table 4. From the 25 normal weight PCOS
patient 19 (73%) had a CCR, while 6 (27%) were CCr. On the other hand from the
25 overweight PCOS patient, 7 (27%) had CCR and 18 (73%) were CCr.
CCR
in; IGTT and NIDDM is shown in Table (5).
Table 6. CCR to 200mg CC in women
with abnormal total cholesterol Tg, HDL, VLDL, LDL, and Atherogenic index.
CC Response |
Normal
No.(%)
|
Abnormal
No.(%)
|
P-value |
|
|
|
|
Ch /CCR |
21 (77.8)
|
5(21.8)
|
(< 0.01) S.
|
Ch/CCr |
6 (22.2)
|
18 (78.2)
|
|
Total |
27 (100)
|
23 (100)
|
|
Tg /CCR |
22 (62.2)
|
4 (28.6)
|
(< 0.05) S |
Tg/CCr |
14 (38.8)
|
10 (71.4)
|
|
Total |
36 (100)
|
14 (100)
|
|
HDL /CCR |
16 (84.3)
|
10 (32.3)
|
(< 0.0001) S
|
HDL/CCr |
3 (15.7)
|
21 (67.7)
|
|
Total |
19 (100)
|
31 (100)
|
|
VLDL/CCR |
21 (56.8)
|
5 (38.5)
|
(> 0.05) NS |
VLDL/CCr |
16 (43.2)
|
8 (61.5)
|
|
Total |
37 (100)
|
13 (100)
|
|
Atherogenic index/CCR |
5 (72.5)
|
11 (37.9)
|
(< 0.0001) S |
Atherogenic index/CCr |
6 (28.5)
|
18 (62.1)
|
|
Total |
21 (100)
|
29 (100)
|
|
PCOS patients were
divided into 3 groups according to the WHO
criteria, 1st group whose BS 2h were normal, 2nd group were IGTT, and the 3rd
group were NIDDM. There was good CCR in the 1st group 81.8%, in the 2nd group
it was only 33.4%, and there was no response in the diabetic group.
CCR
in women with Abnormal Lipid Profile is presented in Tables 6: In PCOS groups
with abnormal and normal cholesterol level, 21.8% and 77.8% had CCR
respectively, with a significant difference at P < 0.01. The normal and
abnormal Tg of PCOS groups showed 62.2%and 28.6% respectively in CCR with significant
difference at (p<0.05). Also there was significant difference observed
between CCR in normal and abnormal HDL (84.3% and 32.3%) were responders
subsequently at (p<0.0001), there was difference observed between normal and
abnormal VLDL of PCOS groups in CCR, as 62.5%, and 10.0% subsequently showed
positive CCR (p<0.01), but there was no significant difference between
normal and abnormal LDL of PCOS groups in CCR (p>0.05), as the normal LDL
PCOS women showed higher percent (56.8%) than abnormal LDL PCOS women (38.5%).
Significant difference was observed between normal and abnormal atherogenic
index in CCR (p<0.0001) as 72.5%, and 37.9% showed CCR subsequently.
DISCUSSION
Research
in the last decade has revealed metabolic stigmata in premenopausal women with
PCOS, such as hypertriglyceridemia, hyperinsulinemia and insulin resistance
(21).In this study evaluation of the post prandial lipemia in PCOS women, and
the respective role of waist to hip ratio (as an indicator of abdominal fat
distribution) on the post prandial lipemia response to high fat containing
meal. Women who are clinically and biochemically defined as PCOS(both normal
weight and over weight groups) found to have higher levels of triglyceride and
cholesterol, LDL, VLDL and atherogenic index were found to be significantly,
and lower level of HDL.
Risk
factors that predispose to heart disease in PCOS patients include dyslipidemia,
impaired glucose tolerance, android obesity, hyperandrogenism and hypertension
(20). So women with PCOS appear at increased cardiovascular risk due to in part
dyslipidemia characterized by increase plasma Tg and reduced (HDL) and they
speculate that altered activity of hepatic lipase or lipid transfer production
could explain this aspect of the dyslipidemia (21). This study showed a
positive correlation between fasting lipid profile and FBS at P < 0.0001.
Hyperinsulinemia
(insulin resistance) appears to be the most important contribution to the lipid
abnormalities particularly the elevation on triglycerides, approximately one
half of patients with PCOS demonstrate insulin resistance (23), patients with
insulin resistance and normal pancreatic B cell function will develop
hyperinsulinemia detected either basally, or following a glucose challenge
(23).
Hyperandrogenism
in women results in higher mean serum Tg and VLDL cholesterol levels, but lower
HDL cholesterol levels (23). The postprandial lipemia response to a high fat
containing meal in this study was positive in all PCOS women, starting at
higher threshold for Tg as mentioned in Table 1, and they had higher
postprandial Tg response than controls. A striking observation from this study
was noticed that non-obese PCOS group had a higher postprandial triglyceride
response than did non-obese control suggesting that even in absence of obesity,
early lipid abnormalities could be present(24).
The
fact that postprandial lipaemia persist for 3-6 h after meal and is exacerbated
by the next meal emphasize the concept that humans are in a postprandial state
for most of each 24 h (25). In both groups of the PCOS a significant
correlation was found at P < 0.0001 between postprandial Tg response and
waist to hip circumference ratio. Postprandial Tg has been found to be
positively correlated with intra abdominal fat in obese women, until now there
have been one report dealing with postprandial lipemia in PCOS patient, which
showed abnormal postprandial pattern in non obese subjects with android body
fat distribution, suggesting that over weight per-se was not the only
determinant of the lipid abnormalities in PCOS women (22). This study confirmed
that postprandial increase in Tg is directly related to its fasting serum
concentration and serum 2h-BS .Hyperinsulinemia leads to increase fasting and
postprandial triglycerides levels(17), and some authors concluded that
postprandial hypertriglyceridemia is associated with increased carotid IMD in
patients with type 2 diabetes and that postprandial
hypertriglyceridemia>2.27 mmol/L may be atherogenic, positive correlation
between the postprandial Tg response to an oral lipid and carotid artery wall
thickness has been reported(24). These studies suggest that prolonged presence
of triglyceride-rich lipoproteins in plasma may indeed play a role in
atherogenesis (25).
PCOS
is associated with infertility due to an ovulation caused by this disorder.
Many treatments can increase both ovulation and fertility rates in these women
(7). PCOS women classified into group II according to WHO classification
system, CC initiation of ovulation is the treatment of choice in this group of
anovulatory women (26). In this study 52% of PCOS patient had response to CC
and 16% of them get pregnancy, in recent study by Marilyne et al; CC
administration result in; ovulation in 50- 60% of PCOS patients, pregnancy in 30%,
and multiple gestation in 3% (27). While in another study by Elizabeth Anna
approximately 80% of women with PCOS will ovulate with CC treatment, and
roughly 60% will conceive (7). It is author tendency not to exceed 150 mg daily
as the likelihood of achieving conception above this dose is poor, and are
usually best treated with gonadotropin (12),but this is expensive and the
condition in the country let to use maximum dose of CC in this study ,and this
might be the cause of low percentage of ovulation in response to CC.
Also
this study showed that women with IGT test and NIDDM were CCR more than PCOS
patients with normal FBS and 2h-BS (18.2%, 66.6%subsequantly), the 6 diabetic
patients (8%) were resistance subsequently, and 73% of these patients with CCR
were over weight. It is more likely that hyperinsulinemia and insulin
resistance contribute to the mechanism of ovulation (20), so all over weight,
anovulatory women with polycystic ovaries are hyperinsulinemic, more CCR, and
the best therapy for these women who are obese is weight loss and
insulin-sensitizing agents alone or as adjuvant to CC (7).
Dyslipidemia
in PCOS women has been reported by several studies, elevated free fatty acid,
Tg and LDL levels and reduced HDL levels relative to age, sex and weight match
control subject were found, insulin rather than androgen levels are correlated
with lipid abnormalities (25).
In
this study there was a positive correlation between abnormal lipid profile and
abnormal FBS and/or 2hrPPBS levels, and evaluation of response to CC on the
PCOS patients with abnormal lipid profile was assessed; there was a significant
difference in CCR between women with; normal and abnormal cholesterol levels at
p<0.01, normal and abnormal Tg levels at p<0.05, normal and abnormal HDL
levels at p<0.0001, normal and abnormal VLDL levels at p<0.01, normal and
abnormal atherogenic index levels at p<0.0001,and no significant difference
in normal and abnormal LDL levels at p>0.05.This type of work had not been
done before, so the results could not be compared with others.
CONCLUSION
Hyperinsulinemia
and insulin resistance contributes to ovulatory disturbance and
hyperandrogenism that is characteristics of PCOS, may also lead to decrease CCR
to ovulation induction in PCOS women. PCOS women with IGTT, NIDDM and abnormal
lipid profile had more CCR in ovulation induction than those with normal BS and
lipid profile, PCOS women had fasting and postprandial hypertriglyceridemia,
which is directly related to high waist-to-hip ratio and insulin resistance
regardless of obesity. This justify intervention trials to asses the benefits
of lowering hyperinsulinemia by losing weight and using of insulin sensitizing
agents in order to achieve a good response to ovulation induction methods.
REFERENCES
- Silva A. Asslanian, Vered D. Lewy and Kapriel Danadian.
2001. Glucose intolerance in obese adolescents with polycystic ovary syndrome:
Roles of insulin resistance and β cells dysfunction and risk of
cardiovascular disease. Clinical Endoc Metab86: 166-71.1
- Cheung PA et al. 1990. Polycystic ovary syndrome. Clin
Obst and Gynecol 33: 655-667.3
- R. Jeffrey Change, MD. 2000. Long term consequences of
polycystic ovary syndrome. Joint ASRM/ESHRE. Reproductive Endocrinology:
congress; Coarse 1.
- Solomon CG. 1999. The epidemiology of polycystic ovary
syndrome, prevalence and associated disease risks. Endocrinol Metab Clin North
Am. Jun; 28(2): 247-63.
- Andrea Dunaif. 1997. Insulin resistance and polycystic
ovary syndrome: Mechanism and implications for pathogenesis. Endocrine Reviews
18(6): 774-800.
- Lergo RS, Spielman R, Urbanek M, Driscol, Strass JF,
Dunaif A. 1998. Phenotype and enotype in polycystic ovary syndrome.
Recent-Prog-Horm-Res; 53: 217-56.
- Sturt Campbell and Ashmonga. 2000. Gynaecology by ten
teachers' seventeenth edition chapter 5 p. 58.
- Saija Korhonen MD, Maritta Hippelainen MD, Leo Niskanen
MD, Maunovanhala MD and Seppo Saarikoski, MD. 2001. Relationship of the
metabolic syndrome and obesity to polycystic ovary syndrome: A controlled
population based study. Am J Obstet Gynecol; 184: 289-96.
- Dunaif A. 1999. Insulin action in the polycystic ovary
syndrome. Endocrinol Metab Clin North Am. Jun; 28(2): 341-59.
- Lergo et al. 1989. Prevalence and predictors of risk for
type 2 diabetes mellitus and impaired glucose tolerance in PCOS. JCEM; 84(1):
165.
- Burghen GA, Givens JR, Kitabchi AE.
1980. Correlation of hyperandrogenism with hyperinsulinism in polycystic
ovarian disease. J Clin Endocrinol Metab; 50: 113-116.
- Howard S. Jacobs's 1995.polycystic ovary syndrome:
aetiology and management. Current opinion in Obstet and Gynecol; 7:203-208.
- Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A,
Licholai T. 1992. Evidence for distinctive and intrinsic defects in insulin
action in polycystic ovary syndrome. Diabetes; 41: 1257-1266.
- Rosenfield RL. 1999. Ovarian and adrenal function in
polycystic syndrome. Endocrinol Metab Clin North Am. Jun; 28(2): 265-93.
- Marshall JC, Eagleson CA. 1999. Neuroendocrine aspects of
polycystic ovary syndrome. Endocrinol Metab Clin North Am. Jun; 28(2): 295-324.
- Warren Kidson. 1998. Polycystic ovary syndrome: A new
direction in treatment. MJA; 169: 537-540.
- Franks S, Gilling Smith C, Watson H, Willis D. 1999.
Insulin action in the normal and polycystic ovary. Endocrinal Metab Clin North
Am. Jun; 28(2): 361-78.
- Vasilios T, Goudas MD and Daniel A, Dumesic MD. 1997.
Polycystic ovary syndrome. Endocrinology and Metabolism Clinics of North AM.
Dec; 26-4.
- Martikainen H, Ruokonen A, Hartikainan AL, Jarvelin MR.
1998. Polycystic ovary syndrome and hyperandrogenism as a risk factor for
cardiovascular disease. Int J Circumpolar Health. Jul; 57(2-3): 133-7.
- Mohammad F. Mitwally M.D., Robert F., Casper MD. 2000. Insulin resistance in polycystic ovary syndrome and the role of oral
hypoglycaemic agents. Middle East Fertility Society J; 5:1.
- Taylor AE. 2000. Insulin-lowing medications in polycystic
ovary syndrome. Obst Gynecol Clin North Am. Sep; 27(3): 483-95.
- Rajkhowa M, Neary RH, Kumpatla P, Gume FL, Jones PW,
Obhrai Clayton RN. 1997. Altered composition of high-density lipoproteins in
women with polycystic ovary syndrome. Clin Endocrinal Metab; 82(10): 339-94.
- Ricardo Azziz. 2000. The relationship of hirsutism,
diabetes and heart disease. American Electrology Association. C.T. 06611,
04/08/1422.
- Teno S, Y Nagashima H, Endoh Y, Omori Y, Takizawa T.
2000. Association of postprandial hypertriglyceridemia and carotid intima-media
thickness in patients with type 2 diabetes. Diabetes Care; 23: 1041-6.
- Cuno S.P.M. Uiterwaal, MD, Diederick E. Grobbee, MD,
Jacqueline CM et al. 1994. Postprandial triglyceride response in young adult
men and familial risk for coronary atherosclerosis. Annals. 15 October; 121:
576-583.
- Bruce R Carr, Richard E Blackwell. 1998. Textbook of
Reproductive Medicine. 2nd ed. Chapter 19, p. 399.
- Guzick D. 1998. Polycystic ovary syndrome: symptomatology
pathophysiology and epidemiology. Am J Obstet Gyn; 179: 589-93.
Copyright © Middle East Fertility Society
|